Flex Biomedical, Inc.
We believe that staying active and maintaining the freedom of movement while minimizing pain is a fundamental necessity.
That's why Flex Biomedical is changing the way we diagnose and treat orthopedic injuries and disease.
Flex Biomedical's lead product is a synthetic polymer, the Flex Polymer™, designed to treat osteoarthritis, an incurable joint disease that affects millions around the world.
The company, which is located in Madison, Wisconsin, was founded in 2007 by Sal Braico, Hideki Suzuki, PhD, Mark Grinstaff, PhD, Michel Wathier, PhD, and Brian Snyder, MD, PhD.